Ekso Bionics Receives FDA Clearance to Market its EksoNR(TM) Robotic Exoskeleton for Use with Multiple Sclerosis Patients

Stock Information for Ekso Bionics Holdings Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ekso Bionics Holdings Inc.

Ekso Bionics to Report First Quarter 2024 Financial Results on April 29, 2024
Ekso Bionics Receives Final Payment Determination for Medicare Reimbursement from the Centers for Medicare & Medicaid Services (CMS) for Ekso Indego Personal
Ekso Bionics Reports Record Annual Revenue of $18.3 Million
Ekso Bionics to Report Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
Ekso Bionics Announces $4.6 Million Registered Direct Offering
Ekso Bionics Launches GaitCoach Software for EksoNR
Ekso Bionics Reports Certain Preliminary Fourth Quarter and Full Year 2023 Financial Results
Ekso Bionics Receives CMS Coding Approval for Ekso Indego Personal

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.